Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo-Reference-Cited by-同舟云学术

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

Published:2016-02-10 Issue:325 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Ashton Susan¹,Song Young Ho²,Nolan Jim²,Cadogan Elaine¹,Murray Jim³,Odedra Rajesh¹,Foster John⁴,Hall Peter A.⁴,Low Susan²,Taylor Paula¹,Ellston Rebecca¹,Polanska Urszula M.¹,Wilson Joanne¹,Howes Colin¹,Smith Aaron¹,Goodwin Richard J. A.⁴,Swales John G.⁴,Strittmatter Nicole⁵,Takáts Zoltán⁵,Nilsson Anna⁶,Andren Per⁶,Trueman Dawn¹,Walker Mike¹,Reimer Corinne L.⁷,Troiano Greg²,Parsons Donald²,De Witt David²,Ashford Marianne³,Hrkach Jeff²,Zale Stephen²,Jewsbury Philip J.¹,Barry Simon T.¹

Affiliation:

1. Oncology iMED, AstraZeneca, Macclesfield, Cheshire SK10 4TG, UK.

2. BIND Therapeutics, 325 Vassar Street, Cambridge, MA 02139, USA.

3. Pharmaceutical Development, AstraZeneca, Macclesfield, Cheshire SK10 2NX, UK.

4. Drug Safety and Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.

5. Department of Surgery and Cancer, Imperial College, London SW7 2AZ, UK.

6. Biomolecular Imaging and Proteomics, National Center for Mass Spectrometry Imaging, Uppsala University, Uppsala 751 05, Sweden.

7. Oncology iMED, AstraZeneca, Gatehouse Park, Waltham, Boston 02451, USA.

Abstract

A nanoparticle formulation of an Aurora B kinase inhibitor uses ion pairing to achieve controlled release and efficacious, nontoxic target inhibition in tumors.

Funder

AstraZeneca

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference27 articles.

1. Nanomedicines for cancer therapy: An update of FDA approved and those under various stages of development;Pillai G.;SOJ Pharm. Pharm. Sci.,2014

2. Nanoparticle Delivery of Cancer Drugs

3. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation;Rahman A. M.;Int. J. Nanomedicine,2007

4. Albumin-bound paclitaxel in solid tumors: clinical development and future directions

5. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of the physical-chemical properties of poly(lactic acid)–poly(ethylene glycol) polymeric nanoparticles on biodistribution;Journal of Controlled Release;2024-01

2. A Comprehensive Review on COVID-19: Emphasis on Current Vaccination and Nanotechnology Aspects;Recent Patents on Nanotechnology;2023-12

3. Hydrophobic ion pairing and microfluidic nanoprecipitation enable efficient nanoformulation of a small molecule indolamine 2, 3‐dioxygenase inhibitor immunotherapeutic;Bioengineering & Translational Medicine;2023-10-28

4. Developing a robust in vitro release method for a polymeric nanoparticle: Challenges and learnings;International Journal of Pharmaceutics;2023-09

5. Evolution of nanomedicine formulations for targeted delivery and controlled release;Advanced Drug Delivery Reviews;2023-09